Kendra Adams, Chief Financial Officer of C4 Therapeutics, Inc., filed a Form 4 on November 13, 2026, reporting the sale of 45,173 shares of common stock on November 12, 2026, pursuant to a Rule 10b5-1 trading plan.
Key Highlights
- Reporting person: Kendra Adams, Chief Financial Officer of C4 Therapeutics, Inc. (NASDAQ:CCCC)
- Transaction: 45,173 shares of common stock disposed of (transaction code S) on November 12, 2026
- Weighted average price: $2.7115 per share, with individual transactions ranging from $2.645 to $2.86, inclusive
- Remaining holdings: 337,150 shares of common stock held directly following the reported transaction
- Trading plan: The sale was executed under a Rule 10b5-1 trading plan adopted on August 13, 2026
- Filing date: November 13, 2026, signed by Shagha Russell as Attorney-in-Fact
CFO Kendra Adams Disposes of C4 Therapeutics Shares Under 10b5-1 Plan
According to the Form 4 filing submitted to the Securities and Exchange Commission, Kendra Adams, serving as Chief Financial Officer of C4 Therapeutics, Inc., disposed of 45,173 shares of the company's common stock on November 12, 2026. The filing identifies C4 Therapeutics under the ticker CCCC on NASDAQ. The transaction was coded "S," indicating a sale, and was reported as a direct ownership transaction.
The filing disclosed that the shares were sold in multiple transactions at prices ranging from $2.645 to $2.86, inclusive, with a weighted average price of $2.7115 per share. The filing noted that Adams "undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected." Following the reported transaction, Adams directly beneficially owned 337,150 shares of C4 Therapeutics common stock.
The filing indicated that the transaction was effected pursuant to a Rule 10b5-1 trading plan that Adams adopted on August 13, 2026. The Form 4 was signed on November 13, 2026, by Shagha Russell, identified as Attorney-in-Fact for the reporting person. No derivative securities transactions were reported in Table II of the filing.
What Was Disclosed
C4 Therapeutics CFO Kendra Adams reported the sale of 45,173 shares of common stock on November 12, 2026, at a weighted average price of $2.7115, under a pre-established Rule 10b5-1 plan, leaving her with 337,150 directly held shares.




Please wait processing your request...